GVN Center/Member Publications

A compilation of GVN GVN Center/Member Academic Publications

Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men
Emerg Microbes Infect. 2021 Oct 28;1-26. doi: 10.1080/22221751.2021.1999777.
Dr. Linfa Wang (Duke-NUS Medical School, Singapore) et al.

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
Nat Commun. 2021 Oct 27;12(1):6197. doi: 10.1038/s41467-021-26499-y.
Drs. Florian Krammer, Adolfo García-Sastre, and Peter Palese (Icahn School of Medicine at Mount Sinai)

A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries (nih.gov)
J Infect. 2021 Oct 1. doi: 10.1016/j.jinf.2021.08.049
Dr. Osbourne Quaye/Ghana (West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana) et al.

SARS-CoV-2 infection generates tissue-localized immunological memory in humans
Sci Immunol. 2021 Oct 7;eabl9105. doi: 10.1126/sciimmunol.abl9105.
Drs. Erica Saphire and Shane Crotty (La Jolla Institute for Immunology) et al.

A highly potent antibody effective against SARS-CoV-2 variants of concern
Cell Rep. 2021 Oct 12;37(2):109814. doi: 10.1016/j.celrep.2021.109814.
Dr. Johan Neyts (Rega Institute for Medical Research, University of Leuven) et al.

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Nat Microbiol. 2021 Oct;6(10):1233-1244. doi: 10.1038/s41564-021-00972-2.
Drs. Pei-Yong Shi (The University of Texas Medical Branch at Galveston) and Matthew Frieman (Institute of Human Virology, University of Maryland) et al.

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
Science. 2021 Sep 14;eabj9853. doi: 10.1126/science.abj9853.
Drs. Alessandro Sette, Shane Crotty and Daniela Weiskopf (La Jolla Institute for Immunology) et al.

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology (Review Article)
Nat Med. 2021 Sep;27(9):1518-1524. doi: 10.1038/s41591-021-01472-w. Epub 2021 Sep 9
Dr. Marion Koopmans (Erasmus MC, the Netherlands) et al.

Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern
Med Microbiol Immunol. 2021 Aug 20 : 1–13. doi: 10.1007/s00430-021-00719-0
Dr. Ulrike Protzer (Institute of Virology, Technical University of Munich) et al.

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.
Dr. Ulrike Protzer (Institute of Virology, Technical University of Munich) et al.

No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing
Cell Rep. 2021 Aug 17;36(7):109530. doi: 10.1016/j.celrep.2021.109530.
Dr. Geoff Falkner (University of Queensland) et al.

Single-amplicon, multiplex real-time RT-PCR with tiled probes to detect SARS-CoV-2 spike mutations associated with variants of concern
J Clin Microbiol. 2021 Aug 25;JCM0144621. doi: 10.1128/JCM.01446-21.
Dr. Raymond Schinazi (Emory University) et al.

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2108453.
Dr. Linfa Wang (Duke-NUS Medical School, Singapore) et al.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Lancet HIV. 2021 Aug 17;S2352-3018(21)00157-0.
Dr. Penny Moore (National Institute for Communicable Diseases, Johannesburg, South Africa) et al.

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Nature. 2021 Aug;596(7871):273-275. doi: 10.1038/s41586-021-03693-y
Drs. Scott Weaver and Pei-Yong Shi (University of Texas Medical Branch) et al.

Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms
iScience DOI: https://doi.org/10.1016/j.isci.2021.102937
Dr. Florian Krammer (Icahn School of Medicine at Mount Sinai, New York) et al.

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Cell Rep. 2021 Jul 27;36(4):109452.
Drs. Pei-Yong Shi (University of Texas Medical Branch) and Erica Saphire (La Jolla Institute for Immunology) et al.

Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic
The Lancet Infectious Disease, August 2, 2021
Marion Koopmans (Erasmus University MC, Netherlands) et al.

Translation from bats to humans beyond infectious diseases
Journal of Experimental Medicine, July 27, 2021
Linfa Wang (Duke-NUS, Singapore) et al.

Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda
Nat Microbiol. 2021 Jun 23. doi: 10.1038/s41564-021-00933-9.
Dr. Pontiano Kaleebu (Uganda Virus Research Institute) et al.

No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing
Cell Reports, July 27, 2021
Dr. Alexander Khromykh (University of Queensland, Australia) et al.

Impact of SARS-CoV-2 variants on the total CD4 + and CD8 + T cell reactivity in infected or vaccinated individuals
Cell Rep Med. 2021 Jul 2;100355. doi: 10.1016/j.xcrm.2021.
Drs. Richard H Scheuermann (J. Craig Venter Institute) and Shane Crotty (Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology) et al.

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Science. 2021 Jul 1;eabh1766. doi: 10.1126/science.abh1766
Dr. Penny Moore (NHLS Johannesburg National Institute for Communicable Diseases, South Africa) et al.

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Cell. 2021 Jun 24;184(13):3426-3437.e8. doi: 10.1016/j.cell.2021.04.025.
Dr. Melanie Ott (Gladstone Institute of Virology and Immunology) et al.

Characterization of a new SARS-CoV-2 variant that emerged in Brazil
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):e2106535118.
Dr. Yoshihiro Kawaoka (University of Wisconsin-Madison Global Health Institute) et al.

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Nature. 2021 Jun 9. doi: 10.1038/s41586-021-03681-2.
Dr. Florian Krammer (Center for Virology at Icahn School of Medicine at Mount Sinai) et al.

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Science. 2021 May 20;eabh1139. doi: 10.1126/science.abh1139
Dr. Ian Wilson (The Scripps Research Institute) et al.

Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
EBioMedicine. 2021 May 24;68:103403. doi: 10.1016/j.ebiom.2021.103403.
Drs. Rana Abdelnab, Robbert Boudewijns, Caroline S Foo, Lorena Sanchez-Felipe, Xin Zhang, Leen Delang, Suzanne J F Kaptein, Kai Dallmeie and Johan Neyts (Rega Institute for Medical Research, University of Leuven) et al.

A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses
Nature Communications, June 8, 2021
Alex Khromykh (University of Queensland, Australia) et al.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Nat Med. 2021 May 17. doi: 10.1038/s41591-021-01377-8

Dr. Kanta Subbarao (The Doherty Institute for Infection and Immunity) et al.

Activate-2: a Double-blind Randomized Trial of BCG Vaccination Against Covid-19 in Individuals at Risk
Medrxiv, May 24, 2021

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
Nature. 2021 Apr 29. doi: 10.1038/s41586-021-03570-8.
Dr. Pardis C Sabeti (Harvard T.H. Chan School of Public Health) et al.

Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics
PNAS, May 2021
GVN Members Dr. Konstantin Chumakov, Christine Benn, Lawrence Blatt, Mihai Netea, and Robert Gallo et al.

Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols
Elife. 2021 Apr 16;10:e65774. doi: 10.7554/eLife.65774.
Dr. Marion Koopmans (Erasmus University Medical Center, Rotterdam, Netherlands) et al.

A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
Nature Biomedical Engineering, May 3, 2021
Dr. Donald Ingber (The Wyss Institute at Harvard, USA) et al.

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Cell Host Microbe. 2021 Apr 15;S1931-3128(21)00181-5. doi: 10.1016/j.chom.2021.04.005.
Dr. Ian Wilson (The Scripps Research Institute) et al.

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV
Nature. 2021 Apr 12. doi: 10.1038/s41586-021-03493-4.
Drs. Ulrike Protzer and Andreas Pichlmair (Institute of Virology, Technical University of Munich, Germany) et al.

Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
Cell Rep Med. 2021 Mar 16;2(3):100208. doi: 10.1016/j.xcrm.2021.100208
Drs. Florian Krammer (Icahn School of Medicine at Mount Sinai, US) and Amy Chung and Sharon Lewin (Peter Doherty Institute for Infection and Immunity, Australia) et al.

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
Lancet Microbe. 2021 Mar 23. doi: 10.1016/S2666-5247(21)00025-2.
Dr. Linfa Wang (DUKE-NUS Medical School) et al.

Systems serology detects functionally distinct coronavirus antibody features in children and elderly
Nature Communications volume 12, Article number: 2037 (2021)
Dr. Amy Chung (Peter Doherty Institute for Infection and Immunity, University of Melbourne Australia) et al.

Pediatric nasal epithelial cells are less permissive to SARS-CoV-2 replication compared to adult cells
Science Direct, March 8, 2021
Dr. Alexander Khromykh (University of Queensland, Australia) et al.

Assessing the potential of unmanned aerial vehicle spraying of aqueous ozone as an outdoor disinfectant for SARS-CoV-2
Science Direct, February 26, 2021
Dr. Alexander Khromykh (University of Queensland, Australia) et al.

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
JAMA. 2021 Mar 1;e213341. doi: 10.1001/jama.2021.3341.
Drs. Matthew Frieman and Mohammad Sajadi (Institute of Human Virology, University of Maryland) et al.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMoa2102214.
Dr. Penny Moore (NHLS Johannesburg National Institute for Communicable Diseases) et al.

TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein. 
2021 Feb 28;13(3):384. doi: 10.3390/v13030384
Kishimoto M, Uemura K, Sanaki T, Sato A, Hall WW, Kariwa H, Orba Y, Sawa H, Sasaki M.Viruses.

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Nat Commun. 2021 Mar 3;12(1):1403. doi: 10.1038/s41467-021-21665-8.
Dr. Kanta Subbarao (The Doherty Institute for Infection and Immunity) et al.

Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
mBio. 2021 Feb 16;12(1):e02492-20. doi: 10.1128/mBio.02492-20.
Drs. Florian Krammer and Benhur Lee (Icahn School of Medicine at Mount Sinai) et al.

TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein
Viruses, February 28, 2021, 13(3), 384; https://doi.org/10.3390/v13030384

Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19
mBio. 2021 Feb 9;12(1):e03192-20. doi: 10.1128/mBio.03192-20.
Dr. David Topham (University of Rochester Medical Center) et al.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Nat Med (2021). https://doi.org/10.1038/s41591-021-01270-4
Dr. Scott Weaver (The University of Texas Medical Branch) et al.

Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2
medRxiv. 2021 Feb 1, 2021. https://doi.org/10.1101/2021.01.30.21250843
Matthew B. Frieman, Mohammad M. Sajadi, et al.

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
Cell Rep. 2021 Jan 21;108728. doi: 10.1016/j.celrep.2021.108728

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
Nature. 2021 Jan 25. doi: 10.1038/s41586-021-03237-4.
Drs. Benhur Lee (Icahn School of Medicine at Mount Sinai) and Scott Weaver (University of Texas Medical Branch) et al.

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike
mBio. 2021 Jan 19;12(1):e02940-20. doi: 10.1128/mBio.02940-20.
Drs. Florian Krammer (Icahn School of Medicine at Mount Sinai) and Yoshihiro Kawaoka (University of Wisconsin-Madison), et al.

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4
Dr. Marion Koopmans (Erasmus University Medical Center Rotterdam, Netherlands) et al.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Science. 2021 Jan 6;eabf4063. doi: 10.1126/science.abf4063.
Drs. Erica Saphire and Shane Crotty (The La Jolla Virus Network) et al.

The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30687-30698. doi: 10.1073/pnas.2012939117. Epub 2020 Nov 12

IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2
J Clin Immunol. 2021 Jan 3;1-2. doi: 10.1007/s10875-020-00933-0
Marc Lecuit, et al.

Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19
Nat Commun. 2020 Nov 11;11(1):5703. doi: 10.1038/s41467-020-19545-8.
Kanta Subbarao and Amy Chung, et al.

A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19
PLOS Biology, November 6, 2020 https://doi.org/10.1371/journal.pbio.3000970
Jae Jung, et al.

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection
Cell. 2020 Oct 20, doi: 10.1016/j.cell.2020.10.028B
Benhur Lee, e.t al

Host-directed editing of the SARS-CoV-2 genome
Biochemical and Biophysical Research Communications, 5 November 2020
William Hall, et al.

SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination
Adv Mater. 2020 Oct 28;e2005637. doi: 10.1002/adma.202005637.
Dr. Luis Martinez-Sobrido (University of Rochester Medical Center), et al.

Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
Cell, November 09, 2020 DOI:https://doi.org/10.1016/j.cell.2020.11.007
Raymond Schinazi et al.

Benchmarking evolutionary tinkering underlying human–viral molecular mimicry shows multiple host pulmonary–arterial peptides mimicked by SARS-CoV-2
Cell Death Discov. 2020; 6: 96. Published online 2020 Oct 2. doi: 10.1038/s41420-020-00321-y
George M. Church et al.

Evidence that coronavirus superspreading is fat-tailed
PNAS first published November 2, 2020; https://doi.org/10.1073/pnas.2018490117
James Collins et al.

Topoisomerase III-β is required for efficient replication of positive-sense RNA viruses
Alexander Bukreyev
Antiviral Res. 2020 Oct; 182: 104874. Published online 2020 Jul 28. doi: 10.1016/j.antiviral.2020.104874

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
Cell, Volume 183, ISSUE 4, P996-1012.e19, November 12, 2020
Katheryn Hastie, Erica Ollmann Saphire et al.

SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig
American Society for Microbiology Journals, Published online October 27, 2020. https://doi.org/10.1128/JVI.01283-20
Michael Farzan et al.

SARS-CoV-2 Community Transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco
Clin Infect Dis. (2020) Aug 21:ciaa1234.
Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, Schwab J, Martinez J, Es DJ, Black D, Gandhi M, Kerkhoff AD, Jain V, Sergi F, Jacobo J, Rojas S, Tulier-Laiwa V, Gallardo-Brown T, Appa A, Chiu C, Rodgers M, Hackett J, Kistler A, Hao S, Kamm J, Dynerman D, Batson J, Greenhouse B, DeRisi J, Havlir DV; CLIAhub Consortium.

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area 
Nature Comm. (2020) Sep 17;11(1):4698.
Ng D, Goldgof G, Shy B, Levine A, Balcerek J, Bapat SP, Prostko J, Rodgers M, Coller K, Pearce S, Franz S, Du L, Stone M, Pillai S, Sotomayor-Gonzalez A, Servellita V, Sanchez-San Martin C, Granados A, Glasner DR, Han LM, Truong K, Akagi N, Nguyen DN, Neumann N, Qazi D, Hsu E, Gu W, Santos YA, Custer B, Green V, Williamson P, Hills NK, Lu CM, Whitman JD, Stramer S, Wang C, Reyes K, Hakim J, Sujishi K, Alazzeh F, Pharm L, Oon CY, Miller S, Kurtz T, Hackett J, Simmons G, Busch MP, Chiu CY.

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay
J Clin Virol. (2020) Sep 16;132:104645.
Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, Prostko J, Nebbia G, Douthwaite S, Rodgers M, Cloherty G

Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community
Open Forum Infectious Diseases. Accepted Oct 2020

Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds
Clinical Infectious Diseases, ciaa1616, https://doi.org/10.1093/cid/ciaa1616 Published Oct 27, 2020
Dr. Andrew Pekosz et al.

Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2
mSphere. 2020 Oct 21;5(5):e00637-20. doi: 10.1128/mSphere.00637-20
Dr. Yoshihiro Kawaoka et al.

A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual
J Transl Med. 2020 Sep 23;18(1):362. doi: 10.1186/s12967-020-02535-1.
Arnaldo Caruso et al.

SARS-CoV-2 vaccine development, access, and equity
J Exp Med. 2020 Nov 2;217(11):e20201288. doi: 10.1084/jem.20201288.
Jerome Kim et al.

Assessment of Real-Time RT-PCR Kits for SARS-CoV-2 Detection
Jpn J Infect Dis. 2020 Sep 24;73(5):366-368. doi: 10.7883/yoken.JJID.2020.108.
Hedeki Hasagawa sept.24, 2020

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
Cell Rep. 2020 Sep 22;32(12):108185. doi: 10.1016/j.celrep.2020.108185.
Yoshio Koyanagi et al.

Suboptimal SARS-CoV-2-specific CD8 + T cell response associated with the prominent HLA-A*02:01 phenotype
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24384-24391. doi: 10.1073/pnas.2015486117.
Peter Doherty et al.

The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions
Life Sci. 2020 Sep 15;257:118075. doi: 10.1016/j.lfs.2020.118075.
Arun Kumar et al.

Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report
Clin Infect Dis. 2020 Oct 9;ciaa1538. doi: 10.1093/cid/ciaa1538.
Dr. Marion Koopmans

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
Lancet Infect Dis. 2020 Sep;20(9):e238-e244. doi: 10.1016/S1473-3099(20)30484-9.
Marion Koopmans, et al.

A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual
J Transl Med. 2020 Sep 23;18(1):362. doi: 10.1186/s12967-020-02535-1.
Arnaldo Caruso, et al.

Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients
Biosens Bioelectron. 2020 Sep 21;169:112643. doi: 10.1016/j.bios.2020.112643.
Dr. David Topham (University of Rochester Medical Center), et al.

Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
Antiviral Research, Volume 182, October 2020, 104924 https://doi.org/10.1016/j.antiviral.2020.104924
Lawrence Blatt, Johan Neyts, et al.

Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomized controlled trial in Denmark
Trials. 2020 Sep 17;21(1):799. doi: 10.1186/s13063-020-04714-3.
Christine Stabell Benn et al.

The non-specific and sex-differential effects of vaccines
Nat Rev Immunol. 2020 Aug;20(8):464-470. doi: 10.1038/s41577-020-0338-x. Epub 2020 May 27.
Christine Stabell Benn et al.

Trained Innate Immunity, Epigenetics, and Covid-19, Sept 10
September 10, 2020, N Engl J Med 2020; 383:1078-1080 DOI: 10.1056/NEJMcibr2011679
Mihai Netea, et al.,

Assessment of Real-Time RT-PCR Kits for SARS-CoV-2 Detection
Jpn J Infect Dis. 2020 Sep 24;73(5):366-368. doi: 10.7883/yoken.JJID.2020.108. Epub 2020 Apr 30.
Hideki Hasegawa

Animal models for COVID-19
Nature. 2020 Sep 23. doi: 10.1038/s41586-020-2787-6.
Neyts, Paul Duprex, Segales et al.

SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes
bioRxiv. 2020 Sep 25;2020.09.24.312553. doi: 10.1101/2020.09.24.312553.
Robert Silverman (Cleveland Clinic)

ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
Nat Immunol. 2020 Oct;21(10):1293-1301. doi: 10.1038/s41590-020-0773-7. Epub 2020 Aug 17.
Sophie Valkenburg (HKU Pasteur)

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Cell. 2020 Aug 20; 182(4): 812–827.e19. Published online 2020 Jul 3. doi: 10.1016/j.cell.2020.06.043
Erica Saphire et al.

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins
Nature 583, 282–285 (2020). https://doi.org/10.1038/s41586-020-2169-0
Edward Holmes (University of Sydney)

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
Emerg Infect Dis. 2020 Jul;26(7):1478-1488. doi: 10.3201/eid2607.200841. Epub 2020 Jun 21.
Marion Koopmans (Erasmus MC), Yazdan Yazdanpanah (REACTING)

Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020
Emerg Infect Dis. 2020 Aug 28;26(12). doi: 10.3201/eid2612.203334.
Dr. Raymond Schinazi (Emory University)

The Origin of COVID-19 and Why It Matters
The American Journal of Tropical Medicine and Hygiene, Volume 103, Issue 3, 2 Sep 2020, p. 955 – 959
William DeLuc (University of Texas Medical Branch) and Peter Doherty (Doherty Institute)

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
N Engl J Med. 2020 Sep 2. doi: 10.1056/NEJMoa2026920
Dr. Matthew Frieman (Institute of Human Virology, University of Maryland)

A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic
Int J Infect Dis. 2020 Aug 22;S1201-9712(20)30681-0. doi: 10.1016/j.ijid.2020.08.052.
Dr. William Hall (University College Dublin, Ireland)

Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
Expert Rev Vaccines. 2020 Aug 24;1-8. doi: 10.1080/14760584.2020.1800463.
Dr. Jerome Kim (International Vaccine Institute, South Korea)

Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
Dr. Albert Osterhaus (University of Hannover, Germany)

Main Routes of Entry and Genomic Diversity of SARS-CoV-2, Uganda
Emerg Infect Dis. 2020 Jul 2;26(10). doi: 10.3201/eid2610.202575.
Dr. Pontiano Kaleebu (Uganda Virus Research Institute)

Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting
J Infect Dis. 2020 Aug 6;jiaa467. doi: 10.1093/infdis/jiaa467
Drs. Damian Purcell, Sharon Lewin, and Kanta Subbarao (The Doherty Institute for Infection and Immunity) has validated five different point-of-care (PoCT)

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Dr. Andrew Pekosz (Johns Hopkins Bloomberg School of Public Health), J Clin Invest. 2020 Aug 7;142004. doi: 10.1172/JCI142004.

SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence
Dr. Marion Koopmans (Erasmus Medical Center, Rotterdam, The Netherlands), J Infect Dis. 2020 Aug 8;jiaa479. doi: 10.1093/infdis/jiaa479

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Drs. Linfa Wang and Antonio Bertoletti (Duke-NUS Medical School, Singapore), Nature 2020 https://doi.org/10.1038/s41586-020-2550-z

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
Stephan Becker (Institute for Virology, Philipps-Universität Marburg, Germany), Cell, 20 August 2020, doi: 10.1016/j.cell.2020.06.044

Connecting clusters of COVID-19: an epidemiological and serological investigation
Co-author Linfa Wang (Duke-NUS, Singapore), Lancet Infectious Diseases, July 2020

Use of Baricitinib in patients with moderate and severe COVID-19.
Co-author Raymond Schinazi (Emory University, USA), Clinical Infectious Diseases, June 2020

Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease.
Co-author Raymond Schinazi (Emory University, USA), Emerging Infectious Diseases, June 2020

Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection.
Co-author Raymond Schinazi (Emory University, USA), medRxiv, May 2020

Phenotype and Kinetics of SARS-CoV-2-specific T Cells in COVID-19 Patients with Acute Respiratory Distress Syndrome
Marion Koopmans (Erasmus University Medical Center, Rotterdam, Netherlands)
Sci. Immun., 26 Jun 2020, 5(48):eabd2071 doi: 10.1126/sciimmunol.abd2071.

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions
Co-Authors Scott Weaver (UTMB, USA) and Robert Garry (Tulane, USA)
Emerging Infectious Diseases, June 22, 2020 doi: 10.3201/eid2609.201806.

Implications of Antibody-Dependent Enhancement of Infection for SARS-CoV-2 Countermeasures 
George Church (The Wyss Institute at Harvard, USA)
Nat Biotechnol. 2020; 10.1038/s41587-020-0577-1.

Can existing live vaccines prevent COVID-19? 
Co-Authors Konstantin Chumakov (Food and Drug Administration, USA) and Robert Gallo (IHV, University of Maryland School of Medicine, USA)
Science, June 12, 2020

Cross-reactive Antibody Response Between SARS-CoV-2 and SARS-CoV Infections
Ian Wilson (The Scripps Research Institute, La Jolla, CA, USA)
Cell Rep, June 2, 2020

COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase
Ramesh Akkina (Colorado State University, USA)
Front. Immunol., May 29, 2020

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance
Journal of Clinical Virology, August 2020

Stat 2 signaling a double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters
Johan Neyts (KU Leuven, Belgium)
bioRxiv, April 2020

Detection of Recombinant Rousettus Bat Coronavirus GCCDC1 in Lesser Dawn Bats (Eonycteris spelaea) in Singapore 
Linfa Wang (Duke-NUS, Singapore)
Viruses, May 2020

A serological assay to detect SARS-CoV-2 seroconversion in humans. 
Florian Krammer (Center for Virology at Icahn School of Medicine at Mount Sinai, USA)
Nature Medicine, May 2020

An Infectious cDNA Clone of SARS-CoV-2
Co-Authors James LeDuc and Scott Weaver (University of Texas Medical Branch, Galveston, TX, USA)
Cell Host Microbe, April 13, 2020

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Marion Koopmans (Erasmus University Medical Center, Rotterdam, Netherlands)
Science, April 17, 2020